ClinicalTrials.gg
CompletedNCT05345691DEVOTEUpdated Sep 9, 2025Results posted

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis, sponsored by Biocon Biologics UK Ltd. Completed at 1 site in United Kingdom. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Biocon Biologics UK Ltd · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Osteoporosis with a site in United Kingdom — 8 open to participants now, 9 under way, none of them phase 3. Osteoporosis · United Kingdom.

Enrollment
10th of 35
479 · median 110
Started
2022
with 1 other
Phase 3
10 of 57
none open now
Registered
45th of 57
by date

Among the 57 studies in Osteoporosis with a site in United Kingdom, this one is the 10th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 in phase 3, and was the 45th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 57 studies in Osteoporosis with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteoporosis with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis

Read the detailed description

The study will consist of 3 study periods: Screening period; Part 1, double-blind active-controlled period; and Part 2, transition period. In the double-blind active-controlled period, eligible Patients will be randomized in a 1:1 ratio to receive either Bmab 1000 or Prolia®. Prior to dosing At Week 52, patients in Prolia® treatment group will be randomized again in a 1:1 ratio to either continue on Prolia® or be transitioned to Bmab 1000. To maintain the study blinding, the patients in the original Bmab 1000 arm will also go through the re-randomization procedure; however, they will continue to receive Bmab 1000. The interventions (Bmab 1000 or Prolia®) will be administered subcutaneously every 6 months. End-of-study visit will be at Week 78 post randomization (Month 18).

03

Conditions studied

  • Postmenopausal Women With Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women, aged ≥55 and \<80 years at screening. Postmenopausal is defined as 12 months of spontaneous amenorrhea with serum FSH (follicle-stimulating hormone) levels ≥40 mIU/mL at screening or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  2. Evidence of osteoporosis as assessed by lumbar spine (L1-L4) absolute BMD corresponding to a T-score classification ≤-2.5 and ≥-4.0.
  3. At least 3 vertebrae in the L1-L4 region and at least one hip joint are evaluable by DXA at screening.
  4. Patients with body weight ≥50 to \<90 kg at screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with T-score of \<-4.0 at the lumbar spine, total hip, or femoral neck.
  2. Known history of previous exposure to denosumab (Prolia®, Xgeva®, or any biosimilar denosumab).
  3. For prior or ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements) following points to be considered for the prior to the screening visit:

    a. Oral bisphosphonate i. Ineligible if used for 3 or more years cumulatively ii. If used for \<3 years, a gap of at least 1 year since the last dose is required at the screening visit b. Dose received any time

  4. Systemic glucocorticosteroids
  5. Patients with ongoing serious infections
  6. Evidence of any of the following per the patient's history, DXA, or X-ray review and/or current disease:

    1. Patient in bed rest for 2 or more weeks during the last 3 months prior to screening
    2. Current hyperthyroidism or hypothyroidism
    3. History and/or current hyperparathyroidism or hypoparathyroidism
    4. Current hypocalcemia or hypercalcemia based on albumin-adjusted serum calcium
    5. Any bone disease including bone or metabolic disease (except for osteoporosis), eg, osteomalacia or osteogenesis imperfecta, rheumatoid arthritis, Paget's disease, ALP (alkaline phosphatase) elevation (at investigator's discretion), Cushing's disease, hyperprolactinemia (at investigator's discretion), fibrous dysplasia, malabsorption syndrome which may interfere with the interpretation of the results
    6. History and/or presence of one severe or 3 or more moderate vertebral fractures
    7. History and/or presence of hip fracture or bilateral hip replacement
    8. Presence of an active healing fracture according to assessment of investigator
    9. History of severe skeletal pain with bisphosphonates which, as per the investigator, is a risk to her participation in the trial
    10. Oral/dental or periodontal conditions:
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    Bmab 1000

    Biological: Bmab 1000

  • Active comparator
    Prolia®:

    Biological: Prolia®

Interventions

  • BiologicalBmab 1000

    60 mg administered as a single SC (subcutaneous) injection once every 6 months.

  • BiologicalDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    60 mg administered as a single SC injection once every 6 months

06

What researchers measure

Primary outcomes

  1. Percentage Change in Lumbar Spine BMD (Bone Mineral Density)

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in lumbar spine BMD

    Time frame: Baseline and Week 52

Secondary outcomes

  1. AUEC (Area Under the Effect Curve) of the Bone Resorption Marker sCTX (Serum C-terminal Telopeptide of Type 1 Collagen)

    To demonstrate pharmacodynamic equivalence between Bmab 1000 and Prolia® based on AUEC of the bone resorption marker sCTX from baseline to week 26

    Time frame: Baseline to Week 26

  2. Percentage Change in Lumbar Spine BMD

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 26 in lumbar spine BMD

    Time frame: Baseline and Week 26

  3. Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD

    Time frame: Baseline upto week 26

  4. Serum Concentrations of P1NP (Procollagen Type 1 N-terminal Propeptide)

    To compare bone turnover between Bmab 1000 and Prolia® based on P1NP after the first dose

    Time frame: Baseline up to Week 52

  5. Incidence of TEAEs (Treatment-emergent Adverse Events) up to 6 Months After the Second Dose

    To compare safety and tolerability of 2 administrations of Bmab 1000 and Prolia® 6 months apart

    Time frame: Baseline up to Week 78

  6. Incidence of ADA (Anti-drug Antibody)

    To compare immunogenicity between Bmab 1000 and Prolia®

    Time frame: Week 78 (Transition Period)

  7. Incidence of ADA (Anti-drug Antibody)

    To compare immunogenicity between Bmab 1000 and Prolia®

    Time frame: Baseline up to Week 52 (Double-blind Active-controlled Period)

  8. Incidence of NAb (Neutralizing Antibody) up to Week 52

    To compare immunogenicity between Bmab 1000 and Prolia®

    Time frame: Baseline up to Week 52 (Double-blind Active-controlled Period)

  9. Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD

    Time frame: Week 52

  10. Incidence of NAb (Neutralizing Antibody) up to Week 52

    To compare immunogenicity between Bmab 1000 and Prolia®

    Time frame: Week 78 (Transition Period)

  11. Percentage Change From Baseline in Hip BMD

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Hip BMD

    Time frame: Week 78

  12. Percentage Change From Baseline in Femoral BMD

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Femoral BMD

    Time frame: Week 78

  13. Minimum Concentration (Cmin) of sCTX

    To compare minimum Concentration (Cmin) of sCTX between Bmab 1000 and Prolia®

    Time frame: baseline to Week 26

  14. Denosumab Concentrations at Weeks 26

    Serum Concentrations of Denosumab

    Time frame: Weeks 26

  15. Denosumab Concentrations at Weeks 52

    Serum Concentrations of Denosumab

    Time frame: Weeks 52

  16. Denosumab Concentrations at Weeks 78

    Serum Concentrations of Denosumab

    Time frame: Weeks 78

  17. Percentage Change From Baseline in Femoral BMD

    To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in Femoral BMD

    Time frame: Week 52

07

Results

Posted Aug 19, 2025

Participant flow

The study was conducted at 42 sites across 4 countries, and enrolled 479 subjects

Part 1
Participant flow — Part 1
MilestonePart 1: Bmab 1000; Part 2: Bmab 1000-Bmab 1000Part 1: Prolia®; Part 2: Prolia®-Bmab 1000Part 1: Not Applicable; Part 2: Prolia®-Prolia®
Started2382400
Completed2182080
Not completed20320
Part 2
Participant flow — Part 2
MilestonePart 1: Bmab 1000; Part 2: Bmab 1000-Bmab 1000Part 1: Prolia®; Part 2: Prolia®-Bmab 1000Part 1: Not Applicable; Part 2: Prolia®-Prolia®
Started218104104
Completed216103103
Not completed211

Outcome measures

PrimaryPercentage Change in Lumbar Spine BMD (Bone Mineral Density)

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in lumbar spine BMD

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent change
Percentage Change in Lumbar Spine BMD (Bone Mineral Density)
Percent changeBmab 1000 and ProliaProlia®
Percentage Change in Lumbar Spine BMD (Bone Mineral Density)1.698 ± 0.51151.440 ± 0.5089
SecondaryAUEC (Area Under the Effect Curve) of the Bone Resorption Marker sCTX (Serum C-terminal Telopeptide of Type 1 Collagen)

To demonstrate pharmacodynamic equivalence between Bmab 1000 and Prolia® based on AUEC of the bone resorption marker sCTX from baseline to week 26

Time frame:
Baseline to Week 26
Reported as:
Mean · day*pg/mL
AUEC (Area Under the Effect Curve) of the Bone Resorption Marker sCTX (Serum C-terminal Telopeptide of Type 1 Collagen)
day*pg/mLBmab 1000Prolia®:
AUEC (Area Under the Effect Curve) of the Bone Resorption Marker sCTX (Serum C-terminal Telopeptide of Type 1 Collagen)127 ± 85.2123 ± 77.3
SecondaryPercentage Change in Lumbar Spine BMD

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 26 in lumbar spine BMD

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent change
Percentage Change in Lumbar Spine BMD
Percent changeBmab 1000Prolia®:
Percentage Change in Lumbar Spine BMD3.872 ± 0.78853.699 ± 0.7860
SecondaryPercentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD

Time frame:
Baseline upto week 26
Reported as:
Least squares mean · Percent change
Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)
Percent changeBmab 1000Prolia®:
Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)1.698 ± 0.51151.440 ± 0.5089
SecondarySerum Concentrations of P1NP (Procollagen Type 1 N-terminal Propeptide)

To compare bone turnover between Bmab 1000 and Prolia® based on P1NP after the first dose

Time frame:
Baseline up to Week 52
Reported as:
Mean · ng/ml
Serum Concentrations of P1NP (Procollagen Type 1 N-terminal Propeptide)
ng/mlBmab 1000Prolia®:
Serum Concentrations of P1NP (Procollagen Type 1 N-terminal Propeptide)69.4 ± 16142.9 ± 94
SecondaryIncidence of TEAEs (Treatment-emergent Adverse Events) up to 6 Months After the Second Dose

To compare safety and tolerability of 2 administrations of Bmab 1000 and Prolia® 6 months apart

Time frame:
Baseline up to Week 78
Reported as:
Count of participants · Participants
Incidence of TEAEs (Treatment-emergent Adverse Events) up to 6 Months After the Second Dose
ParticipantsBmab 1000-Bmab 1000Bmab 1000 -ProliaProlia®:-Prolia
Incidence of TEAEs (Treatment-emergent Adverse Events) up to 6 Months After the Second Dose552927
SecondaryIncidence of ADA (Anti-drug Antibody)

To compare immunogenicity between Bmab 1000 and Prolia®

Time frame:
Week 78 (Transition Period)
Reported as:
Count of participants · Participants
Incidence of ADA (Anti-drug Antibody)
ParticipantsBmab 1000 (Bmab 1000)Bmab 1000 (Prolia)Prolia (Prolia)
Incidence of ADA (Anti-drug Antibody)461314
SecondaryIncidence of ADA (Anti-drug Antibody)

To compare immunogenicity between Bmab 1000 and Prolia®

Time frame:
Baseline up to Week 52 (Double-blind Active-controlled Period)
Reported as:
Count of participants · Participants
Incidence of ADA (Anti-drug Antibody)
ParticipantsBmab 1000Prolia®:
Incidence of ADA (Anti-drug Antibody)215205
SecondaryIncidence of NAb (Neutralizing Antibody) up to Week 52

To compare immunogenicity between Bmab 1000 and Prolia®

Time frame:
Baseline up to Week 52 (Double-blind Active-controlled Period)
Reported as:
Count of participants · Participants
Incidence of NAb (Neutralizing Antibody) up to Week 52
ParticipantsBmab 1000Prolia®:
Incidence of NAb (Neutralizing Antibody) up to Week 5275
SecondaryPercentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD

Time frame:
Week 52
Reported as:
Least squares mean · Percent change
Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)
Percent changeBmab 1000Prolia®:
Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)2.224 ± 0.55322.132 ± 0.5513
SecondaryIncidence of NAb (Neutralizing Antibody) up to Week 52

To compare immunogenicity between Bmab 1000 and Prolia®

Time frame:
Week 78 (Transition Period)
Reported as:
Count of participants · Participants
Incidence of NAb (Neutralizing Antibody) up to Week 52
ParticipantsBmab 1000-Bmab 1000Bmab 1000 - ProliaProlia - Prolia
Incidence of NAb (Neutralizing Antibody) up to Week 52300
SecondaryPercentage Change From Baseline in Hip BMD

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Hip BMD

Time frame:
Week 78
Reported as:
Mean · Percent change
Percentage Change From Baseline in Hip BMD
Percent changeBmab 1000 - Bmab 1000Bmab 1000 - ProliaProlia - Prolia
Percentage Change From Baseline in Hip BMD4.011 ± 2.77444.052 ± 3.43003.483 ± 2.6155
SecondaryPercentage Change From Baseline in Femoral BMD

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Femoral BMD

Time frame:
Week 78
Reported as:
Mean · Percent change
Percentage Change From Baseline in Femoral BMD
Percent changeBmab 1000- Bmab 1000Bmab 1000 - ProliaProlia - Prolia
Percentage Change From Baseline in Femoral BMD3.666 ± 3.66403.333 ± 3.50212.834 ± 3.9551
SecondaryMinimum Concentration (Cmin) of sCTX

To compare minimum Concentration (Cmin) of sCTX between Bmab 1000 and Prolia®

Time frame:
baseline to Week 26
Reported as:
Mean · pg/mL
Minimum Concentration (Cmin) of sCTX
pg/mLBmab 1000Prolia®:
Minimum Concentration (Cmin) of sCTX41.5 ± 18.241.1 ± 17.8
SecondaryDenosumab Concentrations at Weeks 26

Serum Concentrations of Denosumab

Time frame:
Weeks 26
Reported as:
Mean · ng/mL
Denosumab Concentrations at Weeks 26
ng/mLBmab 1000Prolia®:
Denosumab Concentrations at Weeks 2653.6 ± 11940.7 ± 88.1
SecondaryDenosumab Concentrations at Weeks 52

Serum Concentrations of Denosumab

Time frame:
Weeks 52
Reported as:
Mean · ng/mL
Denosumab Concentrations at Weeks 52
ng/mLBmab 1000Prolia®:
Denosumab Concentrations at Weeks 5269.4 ± 16142.9 ± 94.0
SecondaryDenosumab Concentrations at Weeks 78

Serum Concentrations of Denosumab

Time frame:
Weeks 78
Reported as:
Mean · ng/mL
Denosumab Concentrations at Weeks 78
ng/mLBmab 1000 - Bmab 1000Bmab 1000 - ProliaProlia - Prolia
Denosumab Concentrations at Weeks 7887.6 ± 22372.1 ± 17466.2 ± 111
SecondaryPercentage Change From Baseline in Femoral BMD

To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in Femoral BMD

Time frame:
Week 52
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in Femoral BMD
Percent changeBmab 1000Prolia®:
Percentage Change From Baseline in Femoral BMD2.138 ± 0.80421.767 ± 0.7999

Adverse events

Collected over 0- 78 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bmab 10000/342 (0%)15/218 (6.9%)144/218 (66.1%)
Prolia®:1/240 (0.4%)2/104 (1.9%)72/104 (69.2%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventBmab 1000Prolia®:
Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2181/104
Atrial fibrillationCardiac disorders0/2181/104
DizzinessNervous system disorders2/2180/104
Abdominal painGastrointestinal disorders1/2180/104
Gastric ulcerGastrointestinal disorders1/2180/104
Inflammatory bowel diseaseGastrointestinal disorders1/2180/104
UrosepsisInfections and infestations1/2180/104
Vestibular neuronitisInfections and infestations1/2180/104
Musculoskeletal disorderMusculoskeletal and connective tissue disorders1/2180/104
OsteoarthritisMusculoskeletal and connective tissue disorders1/2180/104
Most frequent other events
Showing 10 of 20
Most frequent other events
EventBmab 1000Prolia®:
Upper respiratory tract infectionInfections and infestations18/21812/104
NasopharyngitisInfections and infestations13/2188/104
HypercholesterolaemiaMetabolism and nutrition disorders7/2188/104
COVID-19Infections and infestations10/2187/104
Urinary tract infectionInfections and infestations14/2182/104
SinusitisInfections and infestations0/2186/104
Back painMusculoskeletal and connective tissue disorders12/2183/104
OsteoarthritisMusculoskeletal and connective tissue disorders11/2181/104
HeadacheNervous system disorders11/2185/104
ArthralgiaMusculoskeletal and connective tissue disorders10/2185/104

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bmab 1000Prolia®:Total
<=18 years000
Between 18 and 65 years8488172
>=65 years154153307
Age, Continuous
Age, Continuous(years)Bmab 1000Prolia®:Total
Mean66.7 ± 5.5566.5 ± 5.7766.6 ± 5.66
Sex: Female, Male
Sex: Female, Male(Participants)Bmab 1000Prolia®:Total
Female238241479
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Bmab 1000Prolia®:Total
White237241478
Japanese101
Region of Enrollment
Region of Enrollment(participants)Bmab 1000Prolia®:Total
United Kingdom336
Europe235238473
08

Study locations

1 site
  • PPD Global Ltd, Granta Park, Great Abington,
    Cambridge, UK CB21 6GQ, United Kingdom
09

References and documents

Publications

  • Eastell R, Orwoll E, Cosman F, Plebanski R, Kumar K, Marwah A, Deodhar SS, Wolff-Holz E, Loganathan S. Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis. JBMR Plus. 2026 Apr 11;10(6):ziag062. doi: 10.1093/jbmrpl/ziag062. eCollection 2026 Jun. PubMed 42110973 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2024, 24 months.

Results were first posted in Aug 2025, 1 year 2 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 24 months is close to that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 26, 2022
StartActual
May 24, 2022
Primary completionActual
Jun 12, 2024
CompletionActual
Jun 12, 2024
Results first posted
Aug 19, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05345691
Lead sponsor
Biocon Biologics UK Ltd
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
May 24, 2022
Primary completion
Jun 12, 2024
Completion
Jun 12, 2024
Results posted
Aug 19, 2025
Last update
Sep 9, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion